SP Group A/S
On 15 September, 2020 SP Group initiated a share buy-back programme, cf. company announcement no. 37/2020 of 15 September 2020. According to the programme, SP Group will in the period from 15 September 2020 until 10 April 2021 purchase own shares for a maximum amount of DKK 40.0 million.
The share buy-back programme was initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014 about Market Abuse, the so-called Market Abuse Regulation that protects listed companies’ board and executive board against violation of insider legislation in connection with share buy-backs.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sanofi Winthrop Industrie17.9.2025 07:00:00 CEST | Press release
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Bitget Limited17.9.2025 05:42:07 CEST | Press release
Bitget Turns 7, Coining the ‘Universal Exchange’ as the Next Generation of Exchanges
CGTN17.9.2025 03:06:57 CEST | Pressemeddelelse
CGTN: Film om Japans berygtede biologiske krigsførelsesenhed fra Anden Verdenskrig får premiere den 18. september
Teva Pharmaceutical Industries Ltd16.9.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Society of Actuaries16.9.2025 20:46:16 CEST | Press release
Society of Actuaries Announces Planned CEO Succession in 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom